Vanda Pharmaceuticals (VNDA) Goodwill & Intangibles (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Goodwill & Intangibles of $115.1 million for Q1 2026, up 2.45% on a YoY basis from $112.3 million in Q1 2025, and down 1.7% sequentially from $117.1 million in Q4 2025.
Vanda Pharmaceuticals (VNDA) Goodwill & Intangibles (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of Goodwill & Intangibles data on file, last reported at $115.1 million in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles rose 2.45% year-over-year to $115.1 million; the trailing twelve-month figure through Mar 2026 stood at $115.1 million (up 2.45% YoY), and the FY2025 full-year result was $117.1 million, up 2.62% from the prior year.
- Goodwill & Intangibles eased to $115.1 million in Q1 2026, from $117.1 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $121.4 million in Q4 2023 to a low of $17.4 million in Q3 2023.
- A 5-year average of $75.4 million and a median of $110.6 million in 2025 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles dropped 8.0% in 2023 and surged 564.72% in 2024, its largest moves.
- Tracing VNDA's Goodwill & Intangibles over 5 years: stood at $18.6 million in 2022, then surged by 553.75% to $121.4 million in 2023, then dropped by 5.99% to $114.1 million in 2024, then increased by 2.62% to $117.1 million in 2025, then decreased by 1.7% to $115.1 million in 2026.
- Business Quant data shows VNDA's Goodwill & Intangibles at $115.1 million in Q1 2026, $117.1 million in Q4 2025, and $108.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 311.57 Mn | 109.26 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.10 Mn |
| Dec 31, 2025 | 117.09 Mn |
| Sep 30, 2025 | 108.84 Mn |
| Jun 30, 2025 | 110.59 Mn |
| Mar 31, 2025 | 112.34 Mn |
| Dec 31, 2024 | 114.10 Mn |
| Sep 30, 2024 | 115.85 Mn |
| Jun 30, 2024 | 117.60 Mn |
| Mar 31, 2024 | 119.35 Mn |
| Dec 31, 2023 | 121.37 Mn |
| Sep 30, 2023 | 17.43 Mn |
| Jun 30, 2023 | 17.81 Mn |
| Mar 31, 2023 | 18.19 Mn |
| Dec 31, 2022 | 18.57 Mn |
| Sep 30, 2022 | 18.94 Mn |
| Jun 30, 2022 | 19.32 Mn |
| Mar 31, 2022 | 19.70 Mn |
| Dec 31, 2021 | 20.08 Mn |
| Sep 30, 2021 | 20.45 Mn |
| Jun 30, 2021 | 20.82 Mn |